Meditations on social media

The speed of technology moves can be mind-blowing. It’s seems just yesterday that I had a flip-phone in my pocket with a green screen. Flash-forward to this past weekend and I find myself on a bus departing from New York City bathing in the dim glow of smartphones, laptops, tablets and Kindles.

There’s no doubt the ever-changing communications field has redefined how most people interact, whether they’re in virtual or tangible environments. While there may be an excessive number of discussions in boardrooms, blogs and Silicon Valley on how social media is shaping interpersonal communication, there’s been limited evidence on how social media may affect a physician’s workflow or access to information.

However, researchers from Brigham and Women’s Hospitalin Boston found that social media sites may enhance diabetes management noting that these types of network could be the future poster-children for health promotion as primary care physicians are witnessing increasing patient volume and as a web-savvy population ages and develop chronic diseases.

A report from the Computer Sciences Corporation (CSC) cited a 2011 Nielson and NM Incite statistic that the most popular internet destinations, social networks and blogs, account for 23 percent of total internet time. CSC concluded that organizations cannot afford a “wait-and-see” approach to social media. However, the report also pointed out that “Organizations that use social media risk losing control of their message and risk exposing themselves to privacy, security and ethics breaches."

And this makes perfect sense considering the rapid change that communications has undergone and will continue to go through. However, providers should be thinking and tinkering with social media not only to understand the environment and industry’s capabilities, but also to see what innovative information exchange may be possible when the technology is leveraged. While there is inherent resistence to change, a little exploring into uncharted territory could be a good learning opportunity.

Feel free to contact me to discuss this topic.

Jeff Byers
Content Editor, CMIO
jbyers@trimedmedia.com

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.